In monitoring LVEF for patients receiving pertuzumab, how often should it be checked?

Monitoring left ventricular ejection fraction (LVEF) is critical for patients receiving pertuzumab, especially because this medication is often used in combination therapies that can exacerbate cardiac toxicity. The recommended frequency for checking LVEF is every 6 weeks. This timeline allows clinicians to effectively monitor any potential decline in cardiac function that may arise during treatment.

Checking the LVEF at this interval strikes a balance between ensuring patient safety and managing the logistical aspects of frequent imaging or monitoring, as this frequency is aligned with the pharmacokinetics and potential side effects observed in clinical practice. Regular monitoring at this interval provides timely information that can guide further therapy decisions and ensure that any cardiac side effects are identified early, enabling prompt intervention if necessary.